EXAS - EXACT Sciences - Stock Price & Dividends

Exact Sciences Corporation is a leading provider of innovative cancer screening and diagnostic tests, operating in the United States and globally. The company's flagship product, Cologuard, is a groundbreaking non-invasive stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer, offering a convenient and accurate way to identify potential health risks.

In addition to Cologuard, Exact Sciences offers a range of other diagnostic tests, including the Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, and Oncotype DX Colon Recurrence Score Test. These tests provide valuable insights for healthcare professionals, enabling them to make informed treatment decisions for patients with breast and colon cancer. The company also offers the OncoExTra Test, a tumor profiling solution for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer, helping to identify the most effective treatment options.

Furthermore, Exact Sciences has expanded its portfolio to include Covid-19 testing services, providing critical support during the pandemic. The company is committed to advancing its product pipeline, focusing on enhancing the performance characteristics of Cologuard and developing new blood and fluid-based tests. This dedication to innovation has led to strategic partnerships with esteemed institutions such as the MAYO Foundation for Medical Education and Research and Johns Hopkins University.

Founded in 1995, Exact Sciences Corporation is headquartered in Madison, Wisconsin, and has established itself as a pioneer in the field of cancer diagnostics. With a strong focus on research and development, the company continues to drive progress in the fight against cancer, improving patient outcomes and saving lives.